Please enable JavaScript.

Coggle requires JavaScript to display documents.

Availability, accessibility and affordability of diagnositc tests,…

- - - - Build multiplex disease platform
      - Build laboratory network, equipe with biobank
    - - Build test formats that can be readily adapted to different diseases
- - - - Pooled procurement
      - Advance marketing commitments
    - - Create indirect market interest: ex. create priority review voucher whereby a test developer who produces a test for an NTD can get WHO priority review for another product with commercial interest
  - - - Encourage information sharing, fund joint ventures
- - - - Guild global/cross-region/cross-country training and experience sharing platform, especially south-south training.
  - - - Involve endemic countries into test developer group and collaborate with international developpers
      - Involve manufacturers in the endemic countries to fabricate the assays
  - - - hands-on training/peer learning associated with new diagnostic products
- - - - Clear guidance on processes for validation and approval of new tests (ex. Emergency use listing for Covid 19)
    - - build collaborative arrangement with regulatory authorities
      - build manufacturing regulatory pathway
      - consider alternative pathway for tests which are used for epidemiologic purposes
- - - - case studies of cost saving associated with higher quality diagnostics
      - Add cost-effectiveness analyses in dx test evaluation studies
    - - Include diagnostics in specific diseases investment case
    - - Reach out to national grant awarding bodies across Europe/Americas/Asia, and ask them to set appart a % of funds to support tests that will meet new TPPs